<code id='840177CE24'></code><style id='840177CE24'></style>
    • <acronym id='840177CE24'></acronym>
      <center id='840177CE24'><center id='840177CE24'><tfoot id='840177CE24'></tfoot></center><abbr id='840177CE24'><dir id='840177CE24'><tfoot id='840177CE24'></tfoot><noframes id='840177CE24'>

    • <optgroup id='840177CE24'><strike id='840177CE24'><sup id='840177CE24'></sup></strike><code id='840177CE24'></code></optgroup>
        1. <b id='840177CE24'><label id='840177CE24'><select id='840177CE24'><dt id='840177CE24'><span id='840177CE24'></span></dt></select></label></b><u id='840177CE24'></u>
          <i id='840177CE24'><strike id='840177CE24'><tt id='840177CE24'><pre id='840177CE24'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:27327
          Adam's take main illustration
          Molly Ferguson/STAT

          Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

          What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

          advertisement

          If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul
          Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

          IsraelisblockahighwayastheyprotestagainstplansbyPrimeMinisterBenjaminNetanyahu'sgovernmenttooverhaul

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          Lack of darker skin in textbooks, journals harms patients of color

          HyacinthEmpinado/STATWhendermatologistJennaLesterlearnedthatrashesonskinandtoeswereasymptomofCovid-1